I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

Prelude’s CEO, Kris Vaddi, Ph.D., emphasized the significance of PRT2527’s results while outlining future priorities. “These findings confirm our hypothesis that a selective and potent CDK9 ...

SELLAS focuses on developing innovative cancer therapies, including their lead candidate GPS, which targets the WT1 protein, and SLS009, a small molecule CDK9 inhibitor. SELLAS Life Sciences has ...

The major focus of our research is on the HIV Tat protein, which is essential for HIV transcription, and on two cellular factors, cyclin T1 and Cdk9, which are necessary for Tat function. We are ...